Phase II Study of the Addition of Azacitidine (IND #87574, NSC #102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients with AML
ID Number 58-0056 (100801)Principal Investigator(s)
Luis M. Isola
Department(s) or Division(s)
Hematology and Medical Oncology
The purpose of this study is to find out what effects (good and bad) this study treatment has on you and your type of cancer.
You may qualify to take part in this research study because you have either acute myeloid leukemia (AML) or myelodysplasia (MDS) and are considered a stem cell transplant candidate. This research is being done to see whether or not the outcome of patients diagnosed with MDS and AML who have achieved a complete remission with their initial therapy may be improved..
Stem Cell Transplant remains the standard of care, potentially curative option for patients. This research study is looking at whether the addition of Azacitidine following a Stem Cell Transplant extends disease free survival and overall survival. Azacitidine is not currently approved with use in Stem Cell Transplant but has shown effectiveness in patients with this diagnosis.
Recruiting Patients: No